Patients with newly diagnosed or relapsed/refractory multiple myeloma with high-risk cytogenetics derived a progression-free survival (PFS) benefit from the addition of daratumumab (Darzalex) to a variety of backbone regimens, according to the results of a meta-analysis.
The meta-analysis included data from six phase III trials comparing backbone multiple myeloma regimens with or without daratumumab in patients with high-risk cytogenetics defined as the presence of t(4;14), t(14;16), or del(17p). The addition of daratumumab resulted in improved PFS for patients with newly diagnosed disease (pooled HR 0.67, 95% CI 0.47-0.95, P=0.02) and those with relapsed or refractory disease (pooled HR 0.45, 95% CI 0.30-0.67, P<0.001), reported Smith Giri, MD, MHS, of the University of Alabama at Birmingham, and colleagues in JAMA Oncology.
The positive effect of daratumumab was not weakened by the three trials having different backbone regimens and different age groups, the researchers noted. The meta-analysis found little evidence